New drugs approved for 2014-A Recap of What We’ve Seen This Year

Picture of Phillip Berry

Phillip Berry

Ready to connect?

Schedule a 30-minute discovery call with me today to learn more.

Katherine Lurk, PharmD, VP of Clinical Strategies, Northwind Health

Katherine Lurk, PharmD, BCPS
VP of Clinical Strategies

New-drugs-approved-for-2014-A-Recap-of-What-We’ve-Seen-This-YearAs we look back on 2014, it’s been a big year when it comes to newly approved medications. The FDA has been busy, with a long list of both generic and brand name pharmaceuticals getting their stamp of approval. Let’s talk highlights.

  • Cardiology and Vascular Diseases – Zontivity:  For the reduction of thrombotic cardiovascular events.
  • Family Medicine – Arnuity Ellipta: For the treatment of asthma.
  • Gastroenterology – Cyramza: For the treatment of gastric cancer.
  • Genetic Disease – Alprolix:  For the treatment of hemophilia B.
  • Immunology – Triumeq: For the treatment of HIV-1.
  • Musculoskeletal – Vimizim: For the treatment of Mucopolysaccharidosis type IVA.
  • Nephrology – Harvoni: For the treatment of hepatitis C.
  • Neurology – Belsomra: For the treatment of insomnia.
  • Nutrition and Weight Loss – Contrave: For chronic weight management.

To see a full list of all 2014 FDA approved medications click here.

Available pharmaceuticals change from year to year, with more being added all the time. When you partner with Northwind, you have access to top industry information on the best medications to prescribe to your patients. When drugs become available, we’ll track them down and provide you with a competitive price supported by our responsive customer service. Contact us today to see how our solutions can lead to greater success in 2015.

Share this article

Northwind Health Company is an independent, nationally licensed health management company, providing clinically-driven solutions to 500+ self-funded organizations and over 200,000 members.